Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of ITE in preparation of drugs for preventing and/or treating cardiopulmonary circulatory system diseases

A technology for circulatory system diseases and drugs, applied in the field of medicine, can solve problems that do not involve the new application of ITE in cardiopulmonary circulatory system diseases, and achieve the effect of inhibiting tube formation and promoting value-added

Pending Publication Date: 2020-04-28
GUANGDONG MEDICAL UNIV
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Patent CN106588908A and patent CN102573470A both disclose the application of ITE in the field of tumor prevention and treatment, and neither involves the new application of ITE in cardiopulmonary circulatory system diseases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of ITE in preparation of drugs for preventing and/or treating cardiopulmonary circulatory system diseases
  • Application of ITE in preparation of drugs for preventing and/or treating cardiopulmonary circulatory system diseases
  • Application of ITE in preparation of drugs for preventing and/or treating cardiopulmonary circulatory system diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] This example is the effect of ITE on the phenotype change of transdifferentiated pulmonary artery endothelial cells.

[0032] 1. Experimental materials

[0033] 1. Experimental cells: Human pulmonary artery endothelial cells (HPAECs) were purchased from ScienCell.

[0034] 2. Main reagents: ITE was purchased from Tocris Bioscience (San Diego, CA), endothelial medium (ECM, Cat.#1001) was purchased from ScienCell, fetal bovine serum (FBS), and trypsin were purchased from Gibco, USA The company's products, total protein extract, protease inhibitor, BCA protein concentration determination kit, SDS-PAGE protein loading buffer (5x), ECL chemiluminescence ultrasensitive color development kit were all purchased from Biyuntian (Shanghai) Biological Co., Ltd. , Alexa 488-labeled anti-mouse fluorescent secondary antibody, Alexa 555-labeled anti-rabbit fluorescent secondary antibody was purchased from (Cell Signaling Company), rabbit anti-α-tublin antibody, mouse anti-CD31 ant...

Embodiment 2

[0061] This example is the effect of ITE on hypoxia-induced tube-forming ability of HPAECs transdifferentiated cells

[0062] 1. Experimental materials

[0063] 1. Experimental cells: Human pulmonary artery endothelial cells (HPAECs) were purchased from ScienCell.

[0064] 2. Main reagents: ITE was purchased from Tocris Bioscience (San Diego, CA), endothelial medium (ECM, Cat.#1001) was purchased from ScienCell, fetal bovine serum (FBS), and trypsin were purchased from Gibco, USA The company's product, BrdU antibody, was purchased from Sigma.

[0065] 3. Main experimental instruments: microplate reader is the product of Thermo Company, laser confocal microscope (Japan OLYPUS Company), flow cytometer (BD Company).

[0066] 2. Experimental method

[0067] 1. Matrigel in vitro tube formation assay to detect the tube formation ability of ITE on hypoxia-induced HPAECs transdifferentiated cells

[0068] Melt the Matrigel gel at 4°C overnight, and pre-cool the 24-well plate and t...

Embodiment 3

[0075] This example is the effect of ITE on the proliferation of HPAECs transdifferentiated cells induced by hypoxia

[0076] 1. Experimental materials

[0077] 1. Experimental cells: Human pulmonary artery endothelial cells (HPAECs) were purchased from ScienCell.

[0078] 2. Main reagents: ITE was purchased from Tocris Bioscience (San Diego, CA), endothelial medium (ECM, Cat.#1001) was purchased from ScienCell, fetal bovine serum (FBS), and trypsin were purchased from Gibco, USA The company's product, BrdU antibody was purchased from Sigma.

[0079] 3. Main experimental instruments: microplate reader is the product of Thermo Company, laser confocal microscope (Japan OLYPUS Company), flow cytometer (BD Company).

[0080] 2. Experimental method

[0081] 1. BrdU incorporation rate to detect the effect of ITE on the proliferation of HPAECs transdifferentiated cells induced by hypoxia

[0082] The cells of the above groups were collected and inoculated in laser confocal culture ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to an application of ITE in preparation of drugs for preventing and / or treating cardiopulmonary circulatory system diseases and belongs to the technical field of medicines. In the provided application of the ITE in the preparation of the drugs for preventing and / or treating the cardiopulmonary circulatory system diseases, a structural formula of the ITE is shown in aformula (I). Under hypoxic conditions, the ITE can significantly promote human pulmonary artery endothelial cells (HPEAECs) to be trans-differentiated into smooth muscle-like cells, can significantlypromote proliferation of the smooth muscle-like cells and significantly and significantly inhibits tube-forming ability of the HPEACs, indicating that ITE can be used as an effective target for preventing and / or treating pulmonary artery vascular remodeling, and the ITE can effectively treat the cardiopulmonary circulatory system diseases and provides a new drug selection way for preventing and / ortreating the cardiopulmonary circulatory system diseases.

Description

technical field [0001] The invention relates to the application of ITE in the preparation of medicines for preventing and / or treating cardiopulmonary and circulatory diseases, and belongs to the technical field of medicine. Background technique [0002] Pulmonary artery remodeling (PAR) is pathological changes such as endothelial cell damage, proliferation, and smooth muscle cell proliferation that lead to thickening of the vascular media and occlusion of the lumen of small vessels after the pulmonary artery is stimulated by hypoxia or various injuries. Hypoxic pulmonary hypertension (Hypoxic pulmonary hypertension, HPH) is the main cause that persists and is irreversible, and muscularization of the normally muscle-free small pulmonary arteries is one of the important features of hypoxia-induced PAR. Currently, the origin and mechanism of smooth muscle-like cells during muscularization have not been elucidated. In the past, it was believed that α-SMA-positive cells originat...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/427A61P9/00A61P11/00A61P9/04
CPCA61K31/427A61P9/00A61P11/00A61P9/04
Inventor 雷桅何原王金霞税晓容成俊芬黄石安罗辉
Owner GUANGDONG MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com